Adaptive Biotechnologies Corp (ADPT) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$24.48

From 52W high−73.23%

Volume1.19M

Market cap$3.82B

P/E (TTM)—

P/S (TTM)12.4x

Div yield—

Key dataOct 19, 2026

Open

$24.48

From 52W high

−73.23%

Volume

1.19M

Market cap

$3.82B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−244.1x

P/E (TTM)

—

RSI (14)

36.3

MomentumView details →

1D Return

−0.29%

YTD Return

−62.93%

SummaryUpdated Jun 1, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is a commercial-stage biotechnology company founded in 2009 and headquartered in Seattle, Washington. The company was originally incorporated as Adaptive TCR Corporation before changing its name in December 2011. Adaptive went public in June 2019 and has since established itself as a leader in immune medicine platform development. The company focuses on leveraging the adaptive immune system to develop diagnostic tests and therapeutic treatments for various diseases including cancer, autoimmune conditions, and infectious diseases.

Ask drillr about Adaptive Biotechnologies Corp →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−244.1x

EV/Sales

12.6x

P/S (TTM)

12.4x

P/B (TTM)

26.7x

ProfitabilityView details →

Gross Margin

75.44%

Net Margin

−20.73%

EBITDA Margin

−5.18%

ROE (TTM)

−44.68%

ROA (TTM)

−9.97%

Asset Turnover

0.54x

GrowthView details →

Revenue YoY

+50.13%

EPS YoY

+50.32%

FCF YoY

+70.98%

Revenue CAGR 3Y

+14.34%

EPS CAGR 3Y

+63.89%

EBITDA YoY

+83.82%

MomentumView details →

1D Return

−0.29%

YTD Return

−62.93%

1Y Return

−66.24%

RSI (14)

36.3

vs 50D SMA

−7.94%

vs 200D SMA

−52.67%

Capital & dividendView details →

Debt/Equity

2.87x

Current Ratio

4.79x

Quick Ratio

4.68x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.25

EPS Surprise

−87.11%

Beats (12Q)

8/12

Next Q EPS Est

−$0.07

Avg Surprise (4Q)

−2.37%

Rev Surprise

9.35%

Financials snapshotView financials →

Revenue (TTM)

308.08M

Net Income (TTM)

−63.85M

Op. CF (TTM)

−21.01M

Next earningsNov 4, 2026 →

Latest newsMore news →

Adaptive Biotechnologies announced that it will report its third-quarter 2026 financial results after market close on November 4, 2026, followed by a webcast conference call.5d ago

Adaptive Biotechnologies highlighted the role of its highly sensitive MRD testing in the new International Myeloma Society consensus definition of cure for multiple myeloma, presented at the IMS 23rd Annual Meeting in Glasgow, Scotland.24d ago

Similar companies

Catalyst Pharmaceuticals, Inc.CPRX AbCellera Biologics Inc.ABCL Relay Therapeutics, Inc.RLAY Tango Therapeutics, Inc.TNGX TransThera Sciences (Nanjing) Inc.02617.HK Mirxes Holding Company Limited02629.HK Find similar companies →

Latest newsMore news →

Adaptive Biotechnologies announced that it will report its third-quarter 2026 financial results after market close on November 4, 2026, followed by a webcast conference call.5d ago Adaptive Biotechnologies highlighted the role of its highly sensitive MRD testing in the new International Myeloma Society consensus definition of cure for multiple myeloma, presented at the IMS 23rd Annual Meeting in Glasgow, Scotland.24d ago The National Comprehensive Cancer Network updated its Clinical Practice Guidelines in Oncology for Multiple Myeloma to strengthen routine MRD assessment recommendations and specifically reference Adaptive Biotechnologies' clonoSEQ assay.32d ago